Roche Outlines Use Of Real-World Evidence In Entrectinib NDA

Roche used its Flatiron Health oncology EHR database to generate an external control arm for pivotal single-arm data supporting the personalized medicine candidate, which has an 18 August user fee goal.

Detailed planet earth map_594051395_1200.jpg

Roche turned to its Flatiron Health subsidiary to generate an external control arm of cancer patients with ROS1 mutations to provide a comparator for pivotal single-arm trial data in the new drug application for entrectinib, Roche chief executive officer Bill Anderson told the company’s analyst event on 3 June at the American Society for Clinical Oncology annual meeting. 

Roche acquired Flatiron, an oncology-focused electronic health records company, in 2018. The potential of Flatiron data to generate real-world evidence...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D